Juvenescence
AI-enabled drug discovery, core aging mechanisms, small molecules/biologics/cell therapies
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
AI-enabled drug discovery, core aging mechanisms, small molecules/biologics/cell therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Juvenescence AI-enabled drug discovery, core aging mechanisms, small molecules/biologics/cell therapies
Juvenescence is a clinical-stage AI-enabled biotech company developing medicines intended to extend healthy lifespan. Its programs target core aging mechanisms to treat and prevent age-related diseases, with pipeline areas including cognition, cardio-metabolism, immunity and cellular repair. The company uses the JuvAI platform, including a biomedical knowledge graph, AI chemistry tools and clinical trial analytics, to support drug discovery and development.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Juvenescence — Translational · Bottom quartile. Derived deterministically from 13 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic